Course Overview

This section of the CME course presents physicians with the course description and standards for enduring materials as set forth by the Accreditation Council for Continuing Medical Education (ACCME) and Washington Hospital Center. Complete the Overview by reviewing each of its parts using the links below.

Course Description
Statement of Need	Target Audience
Learning Objectives	Sponsors

Standards for Enduring Materials
CME Accreditation	Method of Participation
Credit Designation	Conflict of Interest Disclosure

Statement of Need

Diabetes mellitus is a complex public health epidemic that will clearly escalate in the future. Estimates indicate that by 2025, approximately 300 million adults worldwide will have diabetes. Despite many advances, the optimal means of restoring and maintaining normoglycemia has yet to be widely implemented. Several factors contribute to this situation. A host of oral antidiabetic agents and insulins are available, and the choice of treatment is complex. This complexity is heightened by the fact that many patients with diabetes have concurrent hypertension and dyslipidemia. In addition, there have been extensive pharmacological advances in these two arenas, which makes the management of a patient with this medical triad a daunting proposition.

This activity presents the highlights of Diabetes Update 2003, a continuing medical education (CME) Conference, held on April 12, 2003, at Washington Hospital Center, Washington, DC.

Learning Objectives

Upon completion of this activity, physicians should be able to:

• Identify the pharmacological options available to treat the patient with diabetes in order to optimize glycemic control, and to use these options clinically
• Utilize information presented to facilitate the therapy of diabetic dyslipidemia
• Demonstrate the ability to treat the patient with hypertension and diabetes and comprehend the utility of the early use of ACE-inhibitors and ARBs
• Recognize how to use combination therapy effectively in patients with type 2 diabetes

Back to Top

Target Audience

This activity is intended for practicing physicians who take care of patients with diabetes, including but not limited to internists, primary care physicians, family practitioners, cardiologists, and nephrologists.

Back to Top

Sponsors

Washington Hospital Center

Washington Hospital Center is a 907-bed, not-for-profit teaching hospital noted for its clinical expertise, innovative medical technology, and patient-centered care. Since 1958, it has set the standard for adult tertiary care in the metropolitan area, providing the area's premier specialty services. Its nationally acclaimed programs include Washington Heart, Endocrinology and Metabolism, Washington Cancer Institute, The Burn Center, MedStar shock/trauma and medical transport services, Women's Services, Transplantation Services, and Washington National Eye Center. Contact Washington Hospital Center for more information.

American Diabetes Association

The American Diabetes Association is the nation's leading nonprofit health organization providing diabetes research, information, and advocacy. The mission of the organization is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To fulfill this mission, the American Diabetes Association funds research, publishes scientific findings and provides information and other services to people with diabetes, their families, health care professionals, and the public. The association is also actively involved in advocating for scientific research and for the rights of people with diabetes. Contact the ADA for more information.

Back to Top

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Washington Hospital Center, MedStar Research Institute, and Clinical CONNEXION. Washington Hospital Center is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation

The Washington Hospital Center designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Back to Top

Method of Participation

This activity should take approximately 3 hours to complete. The participant should, in order, read the learning objectives and presentation summaries, answer the posttest questions, and complete the evaluation. The evaluation provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, and the perception of commercial bias. Credit will be granted through August 22, 2006.

Back to Top

Conflict of Interest Disclosure

As a sponsor accredited by the ACCME, it is the policy of Washington Hospital Center to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest prior to the educational activity. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of a CME activity. For an individual with no relevant financial relationship(s), the participants must be informed that no relevant financial relationship(s) exist.

All faculty are also required to disclose any discussions of unlabeled/unapproved uses of drugs or devices.

The following faculty members have indicated that they have relationships with the following companies, goods or services:

David S.H. Bell, MD, FACE

Grant/Research Support, Consultant, Speakers Bureau, Honorarium:
Aventis Pharmaceuticals, Eli Lilly and Co., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Novo Nordisk

John Buse, MD, PhD, CDE

Grant/Research Support*:
Amylin Pharmaceuticals, Aventis Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Novo Nordisk, Novartis Pharmaceuticals Corporation, Pfizer Inc., Takeda Pharmaceuticals America

Honoraria/Speakers Bureau*:
Aventis Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia & Upjohn, Takeda Pharmaceuticals America

Consultant*:
Amylin Pharmaceuticals, Cygnus, Eli Lilly and Co., Fujisawa Research Institute of America, Novartis Pharmaceuticals Corporation, TheraSense

*These relationships are all under contract between the companies and the University of North Carolina and provided no direct financial benefit to Dr. Buse.

Stock Shareholder:
TheraSense

William Cefalu, MD

Grant/Research Support/Speaker's Bureau:
Dexcom, Novartis Pharmaceuticals Corporation, Pfizer Inc., RW Johnson, Takeda, Aventis, Merck & Co., Inc.

Frederick F. Samaha, MD

Grant/Research Support:
Merck & Co., Inc., GlaxoSmithKline, AstraZeneca LP

The following faculty members have indicated that they have no significant relationship with any company, product, or service being discussed in this program.

Cherrel Christian, RN, CDE
Maria Matas-Chamberlain, RN, CDE
Claudia Morrison, RD, LD, CDE
Yasser Ousman, MD
Meeta Sharma, MD

Back to Top